Cargando…

Cotargeting of XPO1 Enhances the Antileukemic Activity of Midostaurin and Gilteritinib in Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a hematopoietic stem-cell-derived leukemia with often successive derived driver mutations. Late onset acquisition of internal tandem duplication in FLT3 (FLT3-ITD) at a high variant allele frequency often contributes to full transformation to a highly proliferative, r...

Descripción completa

Detalles Bibliográficos
Autores principales:	Brinton, Lindsey T., Sher, Steven, Williams, Katie, Canfield, Daniel, Orwick, Shelley, Wasmuth, Ronni, Cempre, Casey, Skinner, Jordan, Lehman, Amy, Blachly, James S., Byrd, John C., Lapalombella, Rosa
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7352446/ https://www.ncbi.nlm.nih.gov/pubmed/32545904 http://dx.doi.org/10.3390/cancers12061574

Ejemplares similares

Synergistic effect of BCL2 and FLT3 co-inhibition in acute myeloid leukemia
por: Brinton, Lindsey T., et al.
Publicado: (2020)

Targeting OXPHOS de novo purine synthesis as the nexus of FLT3 inhibitor–mediated synergistic antileukemic actions
por: Zhang, Pu, et al.
Publicado: (2022)

Recurrent XPO1 mutations alter pathogenesis of chronic lymphocytic leukemia
por: Walker, Janek S., et al.
Publicado: (2021)

Simultaneous cotargeting of ATR and RNA Polymerase I transcription demonstrates synergistic antileukemic effects on acute myeloid leukemia
por: Wang, Tingting, et al.
Publicado: (2019)

BMX kinase mediates gilteritinib resistance in FLT3-mutated AML through microenvironmental factors
por: Buelow, Daelynn R., et al.
Publicado: (2022)

Prolonged XPO1 inhibition is essential for optimal antileukemic activity in NPM1-mutated AML
por: Pianigiani, Giulia, et al.
Publicado: (2022)

Cotargeting of Mitochondrial Complex I and Bcl-2 Shows Antileukemic Activity against Acute Myeloid Leukemia Cells Reliant on Oxidative Phosphorylation
por: Liu, Fangbing, et al.
Publicado: (2020)

The combination of CUDC-907 and gilteritinib shows promising in vitro and in vivo antileukemic activity against FLT3-ITD AML
por: Qiao, Xinan, et al.
Publicado: (2021)

Gilteritinib Inhibits Glutamine Uptake and Utilization in FLT3-ITD–Positive AML
por: Zavorka Thomas, Megan E., et al.
Publicado: (2021)

Clinical outcomes in patients with relapsed/refractory FLT3-mutated acute myeloid leukemia treated with gilteritinib who received prior midostaurin or sorafenib
por: Perl, Alexander E., et al.
Publicado: (2022)

Gilteritinib, a FLT3/AXL inhibitor, shows antileukemic activity in mouse models of FLT3 mutated acute myeloid leukemia
por: Mori, Masamichi, et al.
Publicado: (2017)

Preclinical efficacy for a novel tyrosine kinase inhibitor, ArQule 531 against acute myeloid leukemia
por: Elgamal, Ola A., et al.
Publicado: (2020)

Genomic analysis of cellular hierarchy in acute myeloid leukemia using ultrasensitive LC-FACSeq
por: Saygin, Caner, et al.
Publicado: (2021)

Correction: Genomic analysis of cellular hierarchy in acute myeloid leukemia using ultrasensitive LC-FACSeq
por: Saygin, Caner, et al.
Publicado: (2021)

Cotargeting among microRNAs in the brain
por: Cherone, Jennifer M., et al.
Publicado: (2019)

Inhibition of Mcl-1 Synergistically Enhances the Antileukemic Activity of Gilteritinib and MRX-2843 in Preclinical Models of FLT3-Mutated Acute Myeloid Leukemia
por: Wu, Shuangshuang, et al.
Publicado: (2022)

Quizartinib, a selective FLT3 inhibitor, maintains antileukemic activity in preclinical models of RAS-mediated midostaurin-resistant acute myeloid leukemia cells
por: Aikawa, Tomoya, et al.
Publicado: (2020)

Next generation XPO1 inhibitor shows improved efficacy and in vivo tolerability in hematologic malignancies
por: Hing, Zachary A., et al.
Publicado: (2016)

Characterization and mitigation of fragmentation enzyme-induced dual stranded artifacts
por: Gregory, Thomas, et al.
Publicado: (2020)

Rare t(X;14)(q28;q32) translocation reveals link between MTCP1 and chronic lymphocytic leukemia
por: Walker, Janek S., et al.
Publicado: (2021)

TP-0903 is active in models of drug-resistant acute myeloid leukemia
por: Jeon, Jae Yoon, et al.
Publicado: (2020)

Invariant NKT cells dictate antitumor immunity elicited by a bispecific antibody cotargeting CD3 and BCMA
por: Casey, Mika, et al.
Publicado: (2022)

PICH and Cotargeted Plk1 Coordinately Maintain Prometaphase Chromosome Arm Architecture
por: Kurasawa, Yasuhiro, et al.
Publicado: (2010)

Production of wax esters in plant seed oils by oleosomal cotargeting of biosynthetic enzymes
por: Heilmann, Mareike, et al.
Publicado: (2012)

A New Compound with Increased Antitumor Activity by Cotargeting MEK and Pim-1
por: Li, Yanan, et al.
Publicado: (2020)

Systematic characterization of seed overlap microRNA cotargeting associated with lupus pathogenesis
por: Kitai, Hiroki, et al.
Publicado: (2022)

Computational Peptide Design Cotargeting Glucagon and Glucagon-like Peptide-1 Receptors
por: Vishnoi, Shubham, et al.
Publicado: (2023)

Clinical potential of midostaurin in advanced systemic mastocytosis
por: Chandesris, Marie Olivia, et al.
Publicado: (2017)

Cotargeting of CYP-19 (aromatase) and emerging, pivotal signalling pathways in metastatic breast cancer
por: Daldorff, Stine, et al.
Publicado: (2017)

MicroRNA-5110 regulates pigmentation by cotargeting melanophilin and WNT family member 1
por: Yang, Shanshan, et al.
Publicado: (2018)

Cotargeting of BTK and MALT1 overcomes resistance to BTK inhibitors in mantle cell lymphoma
por: Jiang, Vivian Changying, et al.
Publicado: (2023)

Midostaurin: an emerging treatment for acute myeloid leukemia patients
por: Gallogly, Molly Megan, et al.
Publicado: (2016)

Real-World Efficacy of Midostaurin in Aggressive Systemic Mastocytosis
por: Szudy-Szczyrek, Aneta, et al.
Publicado: (2021)

Gilteritinib overcomes lorlatinib resistance in ALK-rearranged cancer
por: Mizuta, Hayato, et al.
Publicado: (2021)

A Rare Case of Midostaurin-Associated Sweet's Syndrome
por: Yasin, Hesham, et al.
Publicado: (2022)

Gilteritinib (XOSPATA®) in Turkey: Early Access Program Results
por: Dogu, Mehmet Hilmi, et al.
Publicado: (2023)

Antileukemic activity of novel adenosine derivatives
por: Poczta, Anastazja, et al.
Publicado: (2019)

Large-Scale Drug Screen Identifies FDA-Approved Drugs for Repurposing in Sickle-Cell Disease
por: Cannon, Matthew, et al.
Publicado: (2020)

Cotargeting Plk1 and androgen receptor enhances the therapeutic sensitivity of paclitaxel-resistant prostate cancer
por: Shin, Sol-Bi, et al.
Publicado: (2019)

1126. Three Cases of Neutropenic Enterocolitis Following Midostaurin Administration
por: Carroll, Ryan, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_4749ca9bk8hfnt2pshmatggqrh